Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Case Study: BHP

Procurement and Supply Partner Queries Corporate Philanthropy For any procurement queries, please contact the Institute's Procurement Team. Email:

Discover Series: Cystic fibrosis

What would you discover to help a child? At The Kids, our researchers are committed to Cystic Fibrosis research that makes a real difference.

Giving kids a real second chance after cancer

See how a new comprehensive cancer centre is helping more children survive and thrive.

30 years

In 2020, we celebrated our 30th birthday with those who matter most — the kids whose lives we’ve changed through the research we do.

Research

Socio-economic inequality underpins inequity in influenza vaccination uptake between public and private secondary schools: an Australian population-based study

Socio-economic inequality and vaccination inequity have long been critical issues. However, no studies have explored the gap in influenza vaccination uptake between public and private schools. Importantly, the extent to which socio-economic inequality translates into vaccination uptake inequity has not been quantified.

Research

Modelling Micro-Elimination: Third-Trimester Tenofovir Prophylaxis for Perinatal Transmission of Hepatitis B in the Remote Dolpa District of Nepal

Hepatitis B (HBV) prevalence is very high in pregnant women in the Dolpa district of Nepal, a region characterised by a remote geographic landscape and low vaccination coverage. Using mathematical modelling, we evaluated the impact of third-trimester tenofovir disoproxil fumarate (TDF) prophylaxis on HBV burden and estimated the time required to achieve HBV elimination in Dolpa. 

Research

A New Era for PPARγ: Covalent Ligands and Therapeutic Applications

Peroxisome proliferator-activated receptor γ (PPARγ) is a prominent ligand-inducible transcription factor involved in adipocyte differentiation, glucose homeostasis, insulin sensitivity, inflammation, and cell proliferation, making it a therapeutic target for diabetes, metabolic syndrome, autoimmune diseases, and cancer. 

RESP-ACT

The aim of RESP-ACT is to reduce these children’s respiratory hospital admissions and visits to Emergency Department, and to help them and their families to have as the best possible quality of life.